<DOC>
	<DOCNO>NCT01498653</DOCNO>
	<brief_summary>A randomised , double-blind , double-dummy , parallel group study evaluate efficacy safety fluticasone furoate/vilanterol trifenatate ( FF/VI ) inhalation powder deliver daily treatment asthma adolescent adult subject Asian ancestry currently treat high-strength inhaled corticosteroid mid-strength ICS/LABA combination therapy</brief_summary>
	<brief_title>Evaluating Efficacy Safety Fluticasone Furoate/Vilanterol Trifenatate Treatment Asthma Adolescent Adult Subjects Asian Ancestry</brief_title>
	<detailed_description>This randomize , double-blind , active-comparator , parallel group , multi-center study . At Visit 1 ( Screening Visit ) subject meet inclusion criterion none exclusion criterion enter two week Run-in period . Subjects remain current ICS therapy throughout Run-in period . At end Run-in period ( Visit 2 ) subject meet randomization criterion enter 12 week treatment period receive one two follow treatment : 1 ) FF ( 200mcg ) /VI ( 25mcg ) administer daily even via Novel Dry Powder Inhaler ( NDPI ) 2 ) Fluticasone propionate 500mcg administered twice daily via DISKUS™ Inhaler In addition , subject supply albuterol/salbutamol inhalation aerosol use required treat asthma symptom . Subjects meet randomization criterion Visit 2 withdrawn study . Subjects meet randomization criterion randomize one two treatment group attend clinic 3 on-treatment visit Week 4 ( Visit 3 ) , Week 8 ( Visit 4 ) Week 12 ( Visit 5 ) . Subjects receive treatment 12 week . A Follow-up Visit Contact ( Visit 6 ) take place 1 week complete study medication . All clinic visit take place morning . Subjects participate study maximum 15 week ( Screening Follow-up inclusive ) . A subject regard complete study complete phase study ( Screening , treatment , Follow-up ) .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>1 . Informed Consent : All subject must able willing give write informed consent take part study 2 . Type Subject : Outpatients , Asian ancestry , 12 year age old Visit 1 ( ≥18 year age old local regulation regulatory status study medication permit enrolment adult ) diagnosis asthma define Global Initiative Asthma [ GINA , 2009 ] least 12 week prior Visit 1 . 3 . Gender : Male Eligible Female , define nonchildbearing potential childbearing potential use acceptable method birth control consistently correctly 4 . Severity Disease : A best FEV1 40 % 90 % predict normal value Visit 1 Screening visit . Predicted value base upon NHANES III use Asian adjustment 5 . Reversibility Disease : Demonstrated ≥12 % ≥200mL reversibility FEV1 within 1040minutes follow 24 inhalation albuterol/salbutamol inhalation aerosol ( one nebulized treatment albuterol/salbutamol solution ) Screening Visit . 6 . Current AntiAsthma Therapy : All subject must use ICS , without LABA , least 12 week prior Visit 1 . 7 . ShortActing Beta2Agonists : All subject must able replace current shortacting beta2agonists albuterol/salbutamol inhaler Visit 1 use need duration study . Subjects must able withhold albuterol/salbutamol least 4 hour prior study visit . 1 . History Lifethreatening asthma : Defined protocol asthma episode require intubation and/or associate hypercapnea , respiratory arrest hypoxic seizure within last 10 year . 2 . Respiratory Infection : Culturedocumented suspect bacterial viral infection upper low respiratory tract , sinus middle ear resolve within 4 week Visit 1 lead change asthma management , opinion Investigator , expect affect subject 's asthma status subject 's ability participate study . 3 . Asthma Exacerbation : Any asthma exacerbation require oral corticosteroid within 12 week Visit 1 result overnight hospitalization require additional treatment asthma within 6 month prior Visit 1 . 4 . Concurrent Respiratory Disease : A subject must current evidence pneumonia , pneumothorax , atelectasis , pulmonary fibrotic disease , bronchopulmonary dysplasia , chronic bronchitis , emphysema , chronic obstructive pulmonary disease , respiratory abnormality asthma . 5 . Other Concurrent Diseases/Abnormalities : A subject must clinically significant , uncontrolled condition disease state , opinion investigator , would put safety patient risk study participation would confound interpretation efficacy result condition/disease exacerbate study . 6 . Oropharyngeal Examination : A subject eligible Runin he/she clinical visual evidence candidiasis Visit 1 . 7 . Allergies : Drug Allergy : Any adverse reaction include immediate delay hypersensitivity beta2agonist , sympathomimetic drug , intranasal , inhale , systemic corticosteroid therapy . Known suspected sensitivity constituent new powder inhaler Milk Protein Allergy : History severe milk protein allergy . 8 . Concomitant Medications : Use protocol define prohibited medication within prohibited time interval prior Screening ( Visit 1 ) study . 9 . Tobacco Use : Current smoker smoke history 10 pack year ( e.g. , 20 cigarettes/day 10 year ) . A subject may use inhale tobacco product within past 3 month ( i.e. , cigarette , cigar , smokeless pipe tobacco ) . 10 . Affiliation Investigator 's Site : A subject eligible study he/she immediate family member participate Investigator , sub Investigator , study coordinator , employee participate Investigator . 11 . Previous Participation : A subject may previously randomize treatment another Phase III FF/VI combination product study 12 . Compliance : A subject eligible he/she his/her parent legal guardian infirmity , disability , disease , geographical location seem likely ( opinion Investigator ) impair compliance aspect study protocol , include visit schedule completion daily diary</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>